Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25308 ↗Kurz gefasst
Scoping Review in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Vartika Kesarwani und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Connecticut, Farmington. Hauptthemen laut MEDLINE: Uveitis, Inflammatory Bowel Diseases, Psoriasis, Spondylarthritis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
Extramusculoskeletal manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in ophthalmology, dermatology, and gastroenterology clinics with uveitis, psoriasis, or inflammatory bowel disease (IBD) may have undiagnosed SpA. We set out to identify and evaluate screening tools for SpA in patients with psoriasis, uveitis, and IBD and determine factors that influence the performance of these instruments.
Methods
This scoping review followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. PubMed, Embase, and Web of Science were searched from inception to January 2022.
Results
We identified 13 screening tools for psoriatic arthritis, 2 SpA screening tools for uveitis, and 3 SpA screening tools for IBD. All screening tools were patient‐oriented questionnaires except for the Dublin Uveitis Evaluation Tool, a physician‐applied algorithm. The questionnaires varied in length, scoring method, cutoff score, and spectrum of included SpA features. Average completion time was less than five minutes. Across the three patient populations, the sensitivities and specificities of these screening tools were comparable in the primary validation cohorts. Sensitivities and specificities were generally lower in secondary validation studies, with marked variability among cohorts.
Conclusion
Our results highlight the heterogeneity and limitations of existing SpA screening tools. Although these tools show promise for use within a specific target population, none are generalizable to all patients with extramusculoskeletal manifestations at risk of SpA. Future studies should explore the utility of a generic patient‐oriented SpA screening tool that can be applied to patients with psoriasis, uveitis, or IBD; is easy to use and comprehend; and captures all clinical domains of SpA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Connecticut, Farmington.
- Brigham and Women's Hospital, Boston, Massachusetts.
- Cleveland Clinic, Cleveland, Ohio.
- Stanford University School of Medicine, Stanford, California.
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: M Elaine Husni, Joerg Ermann
Förderung
- NIAMS NIH HHS
- NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Kesarwani, V., Sinnappan, S., Husni, M. E., Weisman, M. H., & Ermann, J. (2024). Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review. Arthritis Care & Research. https://doi.org/10.1002/acr.25308
Vancouver
Kesarwani V, Sinnappan S, Husni ME, Weisman MH, Ermann J. Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review. Arthritis Care & Research. 2024. doi:10.1002/acr.25308
BibTeX
@article{Kesarwani2024,
author = {Kesarwani, Vartika and Sinnappan, Stephanie and Husni, M Elaine and Weisman, Michael H and Ermann, Joerg},
title = {Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25308}
}
EUVIMED